Roivant Sciences (ROIV) Interest Expenses (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Interest Expenses came in at $1.6 billion in Q1 2026, up 127.74% YoY from $701.2 million in Q1 2025, and up 2419495.45% on a QoQ basis from $66000.0 in Q3 2025.
Roivant Sciences (ROIV) Interest Expenses (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 7 years of Interest Expenses data on file, last reported at $1.6 billion in Q1 2026.
- Quarterly Interest Expenses rose 127.74% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 127.74% YoY) and the FY2026 annual result came in at $1.6 billion, up 127.74% from the prior year.
- Interest Expenses improved to $1.6 billion in Q1 2026, from $66000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $1.6 billion in Q1 2026 to a low of $66000.0 in Q3 2025.
- A 5-year average of $171.3 million and a median of $15.6 million in 2022 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 5965.38% in 2025, down 99.94% in 2025.
- Tracing ROIV's Interest Expenses over 5 years: stood at $19.4 million in 2022, then jumped by 42.33% to $27.6 million in 2023, then surged by 310.1% to $113.2 million in 2024, then tumbled by 99.94% to $66000.0 in 2025, then soared by 2419495.45% to $1.6 billion in 2026.
- The last three Interest Expenses figures came in at $1.6 billion (Q1 2026), $66000.0 (Q3 2025), and $184000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 6.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.57 Mn |
| Jun 30, 2026 | 6.57 Mn |
| Mar 31, 2026 | 1.60 Bn |
| Mar 31, 2026 | 1.60 Bn |
| Sep 30, 2025 | 66,000.00 |
| Sep 30, 2025 | 66,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Mar 31, 2025 | 701.22 Mn |
| Mar 31, 2025 | 701.22 Mn |
| Dec 31, 2024 | 113.20 Mn |
| Dec 31, 2024 | 113.20 Mn |
| Sep 30, 2024 | 115.00 Mn |
| Sep 30, 2024 | 115.00 Mn |
| Jun 30, 2024 | 81.40 Mn |
| Jun 30, 2024 | 81.40 Mn |
| Mar 31, 2024 | 11.56 Mn |
| Mar 31, 2024 | 11.56 Mn |
| Dec 31, 2023 | 27.60 Mn |
| Dec 31, 2023 | 27.60 Mn |